NASDAQ: IGMSIgm Biosciences Inc Stock
$1.22+0.03 (+2.52%)
Updated Apr 17, 2025
IGMS Price
$1.22
Fair Value Price
N/A
Market Cap
$72.93M
52 Week Low
$0.92
52 Week High
$22.50
P/E
-0.38x
P/B
1.51x
P/S
138.02x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.68M
Earnings
-$195.80M
Gross Margin
100%
Operating Margin
-7,308.51%
Profit Margin
-7,308.5%
Debt to Equity
4.52
Operating Cash Flow
-$153M
Beta
1.57
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
IGMS Overview
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IGMS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IGMS
Ranked#272 of 463
Ranked#272 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important IGMS news, forecast changes, insider trades & much more!
IGMS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IGMS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IGMS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IGMS is good value based on its book value relative to its share price (1.51x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
IGMS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more IGMS due diligence checks available for Premium users.
Valuation
IGMS fair value
Fair Value of IGMS stock based on Discounted Cash Flow (DCF)
Price
$1.22
Fair Value
-$0.31
Undervalued by
489.97%
IGMS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IGMS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.38x
Industry
-177.72x
Market
27.98x
IGMS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.51x
Industry
4.05x
IGMS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IGMS's financial health
Profit margin
Revenue
$412.0k
Net Income
-$36.6M
Profit Margin
-8,894.9%
IGMS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IGMS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$265.7M
Liabilities
$217.5M
Debt to equity
4.52
IGMS's short-term assets ($193.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IGMS's short-term assets ($193.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IGMS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IGMS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$34.8M
Investing
$18.0M
Financing
$420.0k
IGMS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IGMS vs Biotech Stocks
Igm Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.